No Data
Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter
Express News | Ocean Biomedical- Ownership in Virion to Equal 22% of Virion's Issued & Outstanding Membership Interests, in Exchange for $9 Mln
Express News | Ocean Biomedical- Ratified Fully Countersigned Copy of Revised Agreement With Virion Therapeutics Received on Sept 26
Ocean Biomedical, Molecure Sign Licensing Agreement for YKL-40 Inhibitors
Molecure (WSE: MOC) and Nasdaq-listed Biotechnology Company Ocean Biomedical (NASDAQ: OCEA) Sign an Exclusive Licensing Agreement for the Development and Commercialization of Selective YKL-40 Inhibitors.
Ocean Biomedical's Oncology Platform Included in New Published Study